Regulatory PathRegulatory requirements compared

Active substance

Carboxymethylcellulose

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
UNI FRESH 0.5% UNIT DOSE EYE DROPS0.5 %Eye drops · Ophthalmic use30 Dropper ContainerSAR 17.20Generic · OTCJamjoom Pharmaceuticals Factory CompanyValid
Indications — CHI Daman Drug Formulary

ALLERGIC CONJUCTIVITIS (AC); ANESTHESIA-SUPPORTIVE AGENTS/ EYE DRYNESS IN PATIENTS RECEIVING CONTINUOUS INFUSIONS OF NEUROMUSCULAR BLOCKERS.; OCULAR ROSACEA; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
PRESERVATIVE-FREE THERA TEARS LUBRICANT EYE DROPS022420820.25 % / W/VDROPS · OPHTHALMICMEDTECH PRODUCTS INC
REFRESH CELLUVISC008701531 % / W/VDROPS · OPHTHALMICABBVIE CORPORATION
REFRESH CONTACTS023040150.5 % / W/VSOLUTION · OPHTHALMICABBVIE CORPORATION
REFRESH LIQUIGEL022446501 % / W/VSOLUTION · OPHTHALMICABBVIE CORPORATION
REFRESH PLUS020492600.5 % / W/VDROPS · OPHTHALMICABBVIE CORPORATION
REFRESH TEARS022310080.5 % / W/VDROPS · OPHTHALMICABBVIE CORPORATION
THERATEARS LUBRICANT EYE DROPS022488540.25 % / W/WSOLUTION · OPHTHALMICMEDTECH PRODUCTS INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACREFRESH CELLUVISC 1% EYE GEL$0.36652per EA20 May 2026
US NADACREFRESH LIQUIGEL 1% EYE DROP$0.57805per ML19 Aug 2026
US NADACREFRESH TEARS 0.5% EYE DROP$0.41169per ML20 May 2026
US NADACREFRESH TEARS 0.5% EYE DROP$0.55781per ML19 Aug 2026
US NADACREFRESH TEARS PF 0.5-0.9% DROP$1.2541per ML23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Combinations containing Carboxymethylcellulose

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.